Pfizer completes acquisition of two vaccines

Pfizer Inc. recently announced that it has completed the acquisition of GlaxoSmithKline’s quadrivalent meningococcal ACWY vaccines Nimenrix and Mencevax.

Nimenrix is a vaccine designed to protect against Neisseria meningitidis, an uncommon but highly contagious disease that can lead to disability and death. The vaccine is indicated for all age groups above one year of age. Nimenrix is currently registered and approved for sale in 63 countries across the European Economic Area, Canada, Australia and emerging markets.

Mencevax is a single-dose meningococcal ACWY unconjugated polysaccharide vaccine used to control outbreaks of meningococcal infection and for travelers in countries where the disease is endemic or highly epidemic. Mencevax is indicated for use across all age groups from 2 years of age. Currently, it is registered and approved in 78 countries across Africa, Asia, Australia, Europe, Latin America, Middle East and New Zealand.

“The addition of Nimenrix and Mencevax helps us to fulfill our vision to protect lives with innovative vaccines to fight serious diseases worldwide,” said Susan Silbermann, president and general manager, Pfizer Vaccines. “These vaccines add high-quality and complementary vaccines to our existing portfolio, allowing us to reach a broader global population.”

Pfizer’s global portfolio includes medicines and vaccines as well as many of the world's best-known consumer healthcare products.